Review



ivis lumina iii in vivo imaging system  (Revvity)


Bioz Verified Symbol Revvity is a verified supplier
Bioz Manufacturer Symbol Revvity manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Revvity ivis lumina iii in vivo imaging system
    Ivis Lumina Iii In Vivo Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 37934 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42887606-113-8-15
    Average 96 stars, based on 37934 article reviews
    ivis lumina iii in vivo imaging system - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Reduced neuropeptide signaling attenuates ischemia–reperfusion–induced pressure ulcer formation in SOD1-G93A mice
    Article Snippet: .. The mice were intraperitoneally injected with VivoGlo Luciferin (0.15 mg/g body weight) (Promega, Tokyo, Japan), in PBS and analysed using the in vivo imaging system IVIS (PerkinElmer, MA, USA) according to standard protocols for analysis of spinal cord after removal of dorsal skin tissue. ..

    In Vivo Imaging:

    Article Title: Reduced neuropeptide signaling attenuates ischemia–reperfusion–induced pressure ulcer formation in SOD1-G93A mice
    Article Snippet: .. The mice were intraperitoneally injected with VivoGlo Luciferin (0.15 mg/g body weight) (Promega, Tokyo, Japan), in PBS and analysed using the in vivo imaging system IVIS (PerkinElmer, MA, USA) according to standard protocols for analysis of spinal cord after removal of dorsal skin tissue. ..

    Article Title: Oxygen-augmented erythrocyte-liposome hybrids to overcome paclitaxel resistance in triple-negative breast cancer metastasis via enhanced ferroptosis.
    Article Snippet: .. The in vivo imaging system (IVIS) (PerkinElmer, Caliper IVIS Lumina LT S3) was used to determine the bioluminescence in the lungs of mice on day 5. ..

    Article Title: Mertk drives alveolar bone loss in experimental periodontitis associated with altered neutrophil function and osteoclast recruitment.
    Article Snippet: The neutrophils were plated using the NETosis Assay Kit (Cayman Chemical, Ann Arbor, MI), and 50 μL of 1 mM PMA solutionwas added to half of thewells. .. 17 μg of luminol was added to each well, and the cells were imaged at 405 nm for 2 h with an In Vivo Imaging System (IVIS) (Revvity, Waltham, MA), taking a still image every minute. .. Peak fluorescence was determined using Living Image software (Revvity, Waltham, MA).

    Article Title: Targeting acute kidney injury via inflammation-directed homing using emodin/vitamin E-loaded macrophage membrane-biomimetic nanovesicles.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Article Title: Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody
    Article Snippet: .. Fluorescence living imaging was performed at predetermined time points (6, 12, 24, 48, 72, 96 and 120 h) using an in vivo imaging system (IVIS) (PerkinElmer, MA, USA). .. The acquired images were analyzed using Living Image 4.4 software (PerkinElmer) to quantify fluorescence intensity (expressed as photons/s/cm 2 /sr) within defined tumor regions.

    Article Title: Sustained release PLGA microspheres loaded with a bone-affinity Bmp2 enhance fracture healing and mitigate heterotopic ossification
    Article Snippet: In brief, a firefly luciferase expression plasmid (Beyotime, China) with the smad promoter was transfected into HEK293T cells. .. After 24 h, the medium was changed to contain either Bmp2 or D-Bmp2 in DMEM, and the cells were further cultured for another 24 h. After the supernatant was removed, D-luciferin potassium salt (Beyotime, China) was added, and the firefly fluorescence signal was recorded using an in vivo imaging system (IVIS) (PerkinElmer, USA). .. Circular dichroism (CD) spectroscopy was performed using a Jasco J-1500 CD spectropolarimeter equipped with a Peltier temperature controller to assess the secondary structures of Bmp2 and D-Bmp2.

    Article Title: Glial scar-targeted modification of hepatocyte growth factor-derived peptide for spinal cord injury therapeutic repair
    Article Snippet: .. At 6 h after tail vein administration, the mice were imaged with an in vivo imaging system (IVIS) (PerkinElmer, Waltham, MA, USA) to assess the in vivo fluorescence signal distribution. ..

    Article Title: Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
    Article Snippet: .. Tumor implantation was monitored weekly via bioluminescence imaging Nature Communications Article in Press using the In Vivo Imaging System (IVIS) (PerkinElmer). .. Before imaging, mice were intraperitoneally injected with 150mg/kg D-luciferin potassium salt (PerkinElmer, #122799) dissolved in sterile PBS (Gibco, #10010023) 15min prior to imaging.

    Analysis:

    Article Title: Reduced neuropeptide signaling attenuates ischemia–reperfusion–induced pressure ulcer formation in SOD1-G93A mice
    Article Snippet: .. The mice were intraperitoneally injected with VivoGlo Luciferin (0.15 mg/g body weight) (Promega, Tokyo, Japan), in PBS and analysed using the in vivo imaging system IVIS (PerkinElmer, MA, USA) according to standard protocols for analysis of spinal cord after removal of dorsal skin tissue. ..

    Tissue:

    Article Title: Reduced neuropeptide signaling attenuates ischemia–reperfusion–induced pressure ulcer formation in SOD1-G93A mice
    Article Snippet: .. The mice were intraperitoneally injected with VivoGlo Luciferin (0.15 mg/g body weight) (Promega, Tokyo, Japan), in PBS and analysed using the in vivo imaging system IVIS (PerkinElmer, MA, USA) according to standard protocols for analysis of spinal cord after removal of dorsal skin tissue. ..

    Isolation:

    Article Title: Targeting acute kidney injury via inflammation-directed homing using emodin/vitamin E-loaded macrophage membrane-biomimetic nanovesicles.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Ex Vivo Biodistribution With Gamma Counter:

    Article Title: Targeting acute kidney injury via inflammation-directed homing using emodin/vitamin E-loaded macrophage membrane-biomimetic nanovesicles.
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Fluorescence:

    Article Title: Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody
    Article Snippet: .. Fluorescence living imaging was performed at predetermined time points (6, 12, 24, 48, 72, 96 and 120 h) using an in vivo imaging system (IVIS) (PerkinElmer, MA, USA). .. The acquired images were analyzed using Living Image 4.4 software (PerkinElmer) to quantify fluorescence intensity (expressed as photons/s/cm 2 /sr) within defined tumor regions.

    Article Title: Sustained release PLGA microspheres loaded with a bone-affinity Bmp2 enhance fracture healing and mitigate heterotopic ossification
    Article Snippet: In brief, a firefly luciferase expression plasmid (Beyotime, China) with the smad promoter was transfected into HEK293T cells. .. After 24 h, the medium was changed to contain either Bmp2 or D-Bmp2 in DMEM, and the cells were further cultured for another 24 h. After the supernatant was removed, D-luciferin potassium salt (Beyotime, China) was added, and the firefly fluorescence signal was recorded using an in vivo imaging system (IVIS) (PerkinElmer, USA). .. Circular dichroism (CD) spectroscopy was performed using a Jasco J-1500 CD spectropolarimeter equipped with a Peltier temperature controller to assess the secondary structures of Bmp2 and D-Bmp2.

    Article Title: Glial scar-targeted modification of hepatocyte growth factor-derived peptide for spinal cord injury therapeutic repair
    Article Snippet: .. At 6 h after tail vein administration, the mice were imaged with an in vivo imaging system (IVIS) (PerkinElmer, Waltham, MA, USA) to assess the in vivo fluorescence signal distribution. ..

    Imaging:

    Article Title: Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody
    Article Snippet: .. Fluorescence living imaging was performed at predetermined time points (6, 12, 24, 48, 72, 96 and 120 h) using an in vivo imaging system (IVIS) (PerkinElmer, MA, USA). .. The acquired images were analyzed using Living Image 4.4 software (PerkinElmer) to quantify fluorescence intensity (expressed as photons/s/cm 2 /sr) within defined tumor regions.

    Cell Culture:

    Article Title: Sustained release PLGA microspheres loaded with a bone-affinity Bmp2 enhance fracture healing and mitigate heterotopic ossification
    Article Snippet: In brief, a firefly luciferase expression plasmid (Beyotime, China) with the smad promoter was transfected into HEK293T cells. .. After 24 h, the medium was changed to contain either Bmp2 or D-Bmp2 in DMEM, and the cells were further cultured for another 24 h. After the supernatant was removed, D-luciferin potassium salt (Beyotime, China) was added, and the firefly fluorescence signal was recorded using an in vivo imaging system (IVIS) (PerkinElmer, USA). .. Circular dichroism (CD) spectroscopy was performed using a Jasco J-1500 CD spectropolarimeter equipped with a Peltier temperature controller to assess the secondary structures of Bmp2 and D-Bmp2.

    In Vivo:

    Article Title: Glial scar-targeted modification of hepatocyte growth factor-derived peptide for spinal cord injury therapeutic repair
    Article Snippet: .. At 6 h after tail vein administration, the mice were imaged with an in vivo imaging system (IVIS) (PerkinElmer, Waltham, MA, USA) to assess the in vivo fluorescence signal distribution. ..

    Tumor Implantation:

    Article Title: Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
    Article Snippet: .. Tumor implantation was monitored weekly via bioluminescence imaging Nature Communications Article in Press using the In Vivo Imaging System (IVIS) (PerkinElmer). .. Before imaging, mice were intraperitoneally injected with 150mg/kg D-luciferin potassium salt (PerkinElmer, #122799) dissolved in sterile PBS (Gibco, #10010023) 15min prior to imaging.

    Bioluminescence Imaging:

    Article Title: Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
    Article Snippet: .. Tumor implantation was monitored weekly via bioluminescence imaging Nature Communications Article in Press using the In Vivo Imaging System (IVIS) (PerkinElmer). .. Before imaging, mice were intraperitoneally injected with 150mg/kg D-luciferin potassium salt (PerkinElmer, #122799) dissolved in sterile PBS (Gibco, #10010023) 15min prior to imaging.



    Similar Products

    96
    Revvity ivis lumina iii in vivo imaging system
    Ivis Lumina Iii In Vivo Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42887606-113-8-15
    Average 96 stars, based on 1 article reviews
    ivis lumina iii in vivo imaging system - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity lumina ii in vivo imaging system
    Lumina Ii In Vivo Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42887154-111-49-55
    Average 96 stars, based on 1 article reviews
    lumina ii in vivo imaging system - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity vivo imaging system ivis
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    Vivo Imaging System Ivis, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pmc13669819-248-21-25
    Average 96 stars, based on 1 article reviews
    vivo imaging system ivis - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity vivo bioluminescence imaging
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    Vivo Bioluminescence Imaging, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42874824-117-3-17
    Average 96 stars, based on 1 article reviews
    vivo bioluminescence imaging - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity ivis lumina series iii ex vivo imaging system
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    Ivis Lumina Series Iii Ex Vivo Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42869880-56-25-33
    Average 96 stars, based on 1 article reviews
    ivis lumina series iii ex vivo imaging system - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity optical in vivo imaging system ivis spectrum
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    Optical In Vivo Imaging System Ivis Spectrum, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42886440-284-1-8
    Average 96 stars, based on 1 article reviews
    optical in vivo imaging system ivis spectrum - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity a518 ivis in vivo imaging system perkinelmer ivis lumina xrms microplate reader molecular devices spectramax m5 cell reports 45
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    A518 Ivis In Vivo Imaging System Perkinelmer Ivis Lumina Xrms Microplate Reader Molecular Devices Spectramax M5 Cell Reports 45, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42862722-745-65-71
    Average 96 stars, based on 1 article reviews
    a518 ivis in vivo imaging system perkinelmer ivis lumina xrms microplate reader molecular devices spectramax m5 cell reports 45 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Revvity ivis spectrum in vivo imaging system
    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using <t>IVIS.</t> (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.
    Ivis Spectrum In Vivo Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vivo+imaging+system+ivis/IVIS+optical+imaging+platform/pm42864145-360-6-12
    Average 96 stars, based on 1 article reviews
    ivis spectrum in vivo imaging system - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using IVIS. (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.

    Journal: MedComm

    Article Title: Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody

    doi: 10.1002/mco2.71058

    Figure Lengend Snippet: Tumor‐specific targeting of C33×CD16 in vivo. (A) Experimental workflow of in vivo targeting evaluation. Three nude mouse xenograft models (KMS26, Saos‐2, AU565) were injected Cy5‐C33×CD16 or Cy5‐BB7.2. Images were captured at indicated timepoints using IVIS. (B) Images showing the signal distribution of Cy5‐C33×CD16 or Cy5‐BB7.2 in three xenograft models at 0‐h and 6‐h timepoint. Dashed circles indicate tumor locations. (C–E) Parallel experiment evaluating Cy5‐C33×CD16 biodistribution at 6‐h timepoint. Images show the signal distribution of Cy5‐C33×CD16 in three xenograft models, KMS26 (C), Saos‐2 (D), AU565 (E). (F) Representative images of tumor and five organs showing biodistribution. (G–I) Quantitative analysis of average radiant efficiency in xenografts and five organs from xenograft models, KMS26 (G), Saos‐2 (H), AU565 (I). Data are presented as means ± s.d. (n = 3 biologically independent mice). Statistical significance was determined by one‐way ANOVA followed by Dunnett's multiple comparisons test (all groups vs. KMS26), or by Kruskal–Wallis test followed by Dunn's multiple comparisons test (all groups vs. Saos‐2, all groups vs. AU565). “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001, ns: not significant, p > 0.05.

    Article Snippet: Fluorescence living imaging was performed at predetermined time points (6, 12, 24, 48, 72, 96 and 120 h) using an in vivo imaging system (IVIS) (PerkinElmer, MA, USA).

    Techniques: In Vivo, Xenograft Assay, Injection, Analysis

    Antitumor efficacy of C33×CD16 in vivo. (A–G) Evaluation of antitumor efficacy of C33×CD16. Experimental timeline for animal study (A). KLE xenograft models were established using NSG mice. Mice were intravenously (IV) administered hFc‐C33, C33×CD16, isotype control every 3 days. Survival rate curves for each treatment group, analyzed by the Kaplan–Meier method (B). Statistical significance was determined using the log‐rank test. “*”: p < 0.05, “**”: p < 0.01. Average tumor volume in mice treated with isotype (gray), hFc‐C33 (blue), or C33×CD16 (red) until first death (C). Data represent mean ± S.D.; n = 5 biologically independent mice per group. Tumor growth curves of individual mouse (D). Statistical significance of data on day 37 was determined using one‐way ANOVA followed by Tukey's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001. Representative dot plots show the percentage of infiltrating NK92mi‐CD16a cells (CD56 + ) in tumor tissue (E). Statistical result shows the percentage of infiltrating NK92mi‐CD16a cells (CD56 + ) in tumor tissue (F). Statistical result shows the counts of infiltrating NK92mi‐CD16a cells (CD56 + ) secreting IFN‐γ per million cells (G). Data represent mean ± s.d.; n = 5 biologically independent mice per group. Statistical significance determined using Kruskal–Wallis test followed by Dunn's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, ns: not significant, p > 0.05. (H–J) Evaluation of antitumor efficacy of C33×CD16 combined with adoptive NK cell transfer. Experimental timeline (H). Xenograft models were established by IV injection of KMS26‐luc cells into NSG mice. Mice were IV administered hFc‐C33, C33×CD16, isotype control every 3 days. (I) Average tumor volume in mice treated with isotype (gray), hFc‐C33 (blue), or C33×CD16 (red) until day 20. (J) IVIS imaging of individual mice on days 5, 10, 20 post‐treatments. Orange circle: location of metastatic lesion. Data represent mean ± s.d.; n = 5 biologically independent mice per group. Statistical significance of data on day 20 was determined using Kruskal–Wallis test followed by Dunn's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, ns: not significant, p > 0.05. Partially created in BioRender. Wu, H. (2026) https://BioRender.com/7z2oryq .

    Journal: MedComm

    Article Title: Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody

    doi: 10.1002/mco2.71058

    Figure Lengend Snippet: Antitumor efficacy of C33×CD16 in vivo. (A–G) Evaluation of antitumor efficacy of C33×CD16. Experimental timeline for animal study (A). KLE xenograft models were established using NSG mice. Mice were intravenously (IV) administered hFc‐C33, C33×CD16, isotype control every 3 days. Survival rate curves for each treatment group, analyzed by the Kaplan–Meier method (B). Statistical significance was determined using the log‐rank test. “*”: p < 0.05, “**”: p < 0.01. Average tumor volume in mice treated with isotype (gray), hFc‐C33 (blue), or C33×CD16 (red) until first death (C). Data represent mean ± S.D.; n = 5 biologically independent mice per group. Tumor growth curves of individual mouse (D). Statistical significance of data on day 37 was determined using one‐way ANOVA followed by Tukey's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, “***”: p < 0.001. Representative dot plots show the percentage of infiltrating NK92mi‐CD16a cells (CD56 + ) in tumor tissue (E). Statistical result shows the percentage of infiltrating NK92mi‐CD16a cells (CD56 + ) in tumor tissue (F). Statistical result shows the counts of infiltrating NK92mi‐CD16a cells (CD56 + ) secreting IFN‐γ per million cells (G). Data represent mean ± s.d.; n = 5 biologically independent mice per group. Statistical significance determined using Kruskal–Wallis test followed by Dunn's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, ns: not significant, p > 0.05. (H–J) Evaluation of antitumor efficacy of C33×CD16 combined with adoptive NK cell transfer. Experimental timeline (H). Xenograft models were established by IV injection of KMS26‐luc cells into NSG mice. Mice were IV administered hFc‐C33, C33×CD16, isotype control every 3 days. (I) Average tumor volume in mice treated with isotype (gray), hFc‐C33 (blue), or C33×CD16 (red) until day 20. (J) IVIS imaging of individual mice on days 5, 10, 20 post‐treatments. Orange circle: location of metastatic lesion. Data represent mean ± s.d.; n = 5 biologically independent mice per group. Statistical significance of data on day 20 was determined using Kruskal–Wallis test followed by Dunn's multiple comparisons test. “*”: p < 0.05, “**”: p < 0.01, ns: not significant, p > 0.05. Partially created in BioRender. Wu, H. (2026) https://BioRender.com/7z2oryq .

    Article Snippet: Fluorescence living imaging was performed at predetermined time points (6, 12, 24, 48, 72, 96 and 120 h) using an in vivo imaging system (IVIS) (PerkinElmer, MA, USA).

    Techniques: In Vivo, Xenograft Assay, Control, Tissue, IV Injection, Imaging